Cyclosporin A Enhances Callus Formation in Rabbit Tibia Fractures - International Journal of Clinical Medicine

IJCM > Vol.4 No.7, July 2013

Cyclosporin A Enhances Callus Formation in Rabbit Tibia Fractures ()

HTML

Download as PDF (Size: 478KB) PP. 28-33

DOI: 10.4236/ijcm.2013.47A1005 4,269 Downloads 5,664 Views Citations

Author(s)

Anders L. Ekelund, Olle Nilsson

Affiliation(s)

Department of Orthopedic Surgery, St. G?ran’s Hospital, Stockholm, Sweden.
Department of Orthopedic Surgery, Uppsala Uni- versity Hospital, Uppsala University, Uppsala, Sweden..

ABSTRACT

Purpose: Drugs that modify the production of cytokines may affect fracture healing.The immunosuppressive drug cyclosporin A is widely used to modify the immune response in transplantations and in treatment of rheumatoid disorders. We wanted to analyze the effect of cyclosporin A on fracture healing and on the development of trauma induced osteopenia.Methods: Experimental tibia fractures were stabilised with intramedullary pins in 26 rabbits. The animals were given 5mg/kg/day of cyclosporin A or placebo for 5 weeks. Bone mineral content, callus volume and biomechanical testing were performed on both tibias and femurs.Results: At 5 weeks cyclosporin A treatment resulted in increased bone mineral content and increased callus volume of the fractured bone. The femora on the operated side had significantly lower bone mineral content compared to the non-operated side. This trauma induced osteopenia was unaffected by cyclosporin A treatment. Failure torque and stiffness of the tibia and femora were similar in both groups.Interpretation: Cyclosporin A stimulates bone formation in fracture repair. The mechanism is unclear, but a direct or cytokine mediated effect on bone forming cells, or enhanced bone induction resulting in increased bone formation, is possible.

KEYWORDS

Callus; Cyclosporin A; Osteopenia; Tibia Fractures

Share and Cite:

A. Ekelund and O. Nilsson, "Cyclosporin A Enhances Callus Formation in Rabbit Tibia Fractures," International Journal of Clinical Medicine, Vol. 4 No. 7A, 2013, pp. 28-33. doi: 10.4236/ijcm.2013.47A1005.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies